
Revier launches into cardiometabolic disease market with €6m
Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations. The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases. The financing was led by the KHAN… Read More
